New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
08:19 EDTBSXBoston Scientific to expand restructuring, sees cutting 900-1,000 jobs
The company announced earlier an expansion of its 2011 restructuring program. The company estimates that the Expansion will reduce gross annual pre-tax operating expenses by approximately $100M-$115M exiting 2013; and that the total 2011 restructuring program, including the Expansion, will reduce gross annual pre-tax operating expenses by approximately $340M-$375M exiting 2013. The company anticipates the reduction of 900 to 1,000 positions worldwide through a combination of employee attrition and targeted headcount reductions as a result of the Expansion. The company estimates that the implementation of the Expansion will result in total pre-tax charges of approximately $140M-$160M, and that approximately $100M-$120M of these charges will result in future cash outlays. The company estimates that the implementation of the Total Program will result in total pre-tax charges of approximately $300M-$355M, and that approximately $270M-$300M of these charges will result in future cash outlays.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
16:11 EDTBSXBoston Scientific enrolls first patient REDUCE-HTN: REINFORCE study
Boston Scientific announced the first patient in the REDUCE-HTN: REINFORCE study was enrolled this week at Cardiology P.C. at Princeton Baptist Medical Center in Birmingham, AL by Farrell Mendelsohn, M.D., site principal investigator, and referred by Michael Wilensky, M.D. Boston Scientific received an investigational device exemption, or IDE, for the study from the FDA in December.
April 14, 2015
09:09 EDTBSXBoston Scientific announces strategic alliance with Frankenman
Boston Scientific announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader with deep local market expertise in the China surgical devices market. This alliance is expected to enable Boston Scientific and Frankenman to reach more clinicians and treat more patients by providing access to training on less invasive endoscopic technologies and the clinical and economic benefits these therapies can provide. CPEChina Fund, an entity of CITIC PE, is a current shareholder of Frankenman and will continue to support the company's growth in alignment with this strategic partnership.Under the terms of the agreement, Boston Scientific will become a shareholder of Frankenman, and provide services and expertise to Frankenman to support its continued growth, development pipeline and manufacturing capabilities. The transaction is expected to close in the first half of 2015, subject to customary closing conditions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use